Tfpi - tissue factor pathway inhibitor Gene

Also Known as EPI; LACI; A630013F22Rik

Species: Mus musculus

Gene Type: protein coding
Gene ID: 21788

Summary

Predicted to enable serine-type endopeptidase inhibitor activity. Predicted to be involved in negative regulation of blood coagulation. Predicted to act upstream of or within blood coagulation. Located in extracellular space. Is expressed in several structures, including central nervous system; hemolymphoid system; liver; lung; and retina. Human ortholog(s) of this gene implicated in several diseases, including Factor VIII deficiency; osteonecrosis; thrombophilia (multiple); toxic shock syndrome; and transient cerebral ischemia. Orthologous to human TFPI (tissue factor pathway inhibitor). [provided by Alliance of Genome Resources, Apr 2022]

Tfpi Products (5)

mRNA Protein Name
NM_001177319.1 NP_001170790.1 tissue factor pathway inhibitor isoform b precursor
NM_001177320.1 NP_001170791.1 tissue factor pathway inhibitor isoform b precursor
NM_001355271.1 NP_001342200.1 tissue factor pathway inhibitor isoform a precursor
NM_001355273.1 NP_001342202.1 tissue factor pathway inhibitor isoform a precursor
NM_011576.1 NP_035706.1 tissue factor pathway inhibitor isoform a precursor
Protein Preferred Names Protein Names

tissue factor pathway inhibitor

  • extrinsic pathway inhibitor

  • lipoprotein-associated coagulation inhibitor

Recombinant Tfpi Proteins

Cat. No. Product Name Accession Purity
HY-P73425 TFPI Protein, Mouse (HEK293, His) NP_035706.1 (L29-K289) ≥ 95%, as determined by reducing SDS-PAGE.
HY-P73425A TFPI Protein, Mouse (HEK293, C-His) O54819-1 (L29-K289) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99283 Concizumab 98.12% Unkown

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-153480A ARC19499 sodium Inhibitor 99.40% Phase 1
Inhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Phase
HY-P99725 Marstacimab 96.27% Phase 3
HY-P99465 Befovacimab Inhibitor 97.31% Phase 2

Pre-clinical Phase

Bioactive Molecules (7)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-153480 ARC19499 Inhibitor 93.65% Unkown
HY-RS14427 TFPI Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS14428 TFPI2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS17298 Tfpi Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS18411 Tfpi2 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23753 Tfpi Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS24892 Tfpi2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P991379 MG1113A Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Tfpi NCBI NCBI:7035